UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043114
Receipt number R000049168
Scientific Title Effect of food containing algae intake on metabolic syndrome related factor : A randomized double-blind placebo-controlled study
Date of disclosure of the study information 2022/01/24
Last modified on 2021/09/30 18:07:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of food containing algae intake on metabolic syndrome related factor

Acronym

Effect of food containing algae intake on metabolic syndrome related factor

Scientific Title

Effect of food containing algae intake on metabolic syndrome related factor : A randomized double-blind placebo-controlled study

Scientific Title:Acronym

Effect of food containing algae intake on metabolic syndrome related factor

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is investigate the effects of test food intake for 12 weeks on metabolic syndrome related factor

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Visceral fat area, body fat percentage, HDL-cholesterol, triglyceride, fasting blood sugar, waist circumference, systolic blood pressure, diastolic blood pressure, LDL-cholesterol

Key secondary outcomes

1)Subcutaneous fat area, total fat area, weight
2)adiponectin, leptin, free fatty acids, Insulin, HOMA-R, HbA1c, Total cholesterol
3)Immunoglobulin, anti-paramylon antibody titer
4) questionnaire survey about physical condition, defecation behavior, eating behavior, exercise behavior


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Intake test food thrice daily for 12 weeks.

Interventions/Control_2

Intake control food thrice daily for 12 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1)Healthy Japanese women and men, between 20 and 64 years age when consent acquisition.
2)Body mass index of 24 to 30kg/m2
3)Waist circumference condition (>=85cm Male, >=90cm female)
4) Subjects who are no planned to change their lifestyle.
5) Individuals who don't have irregular or disturbed life style such as night shifts.
6)Subjects who have received enough explanation about this study and were able to understand that, then giving written informed consent.

Key exclusion criteria

1)At least one previous medical history of malignant tumor, heart failure or myocardial infraction
2) Currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus.
3) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ).
4)Subjects who excessive alcohol intake.
5)Subjects who are allergic to medicines and/or the test food related products.
6)Subjects who took part in another clinical study within 3 months prior to the start of the present study.
7)Subjects who routinely intake supplements such as euglena, chlorella, spirulina, beta-glucan and supplement that may decrease the visceral fat level, cholesterol and blood sugar level.
8) Subjects are taking warfarin and the investigator has determined that it is inappropriate for this study.
9)Females who are pregnant or lactating, and females who could become pregnant or lactating during test period.
10)Subjects with abnormal food habit or irregular life style such as shifts workers or late-night workers.
11) Subjects who suffer from severe anemia
12)Subjects having blood sample 400mL or more taken within 3 months prior to the start of the present study (e.g. donated blood).
13)Subjects have some designed infectious disease.
14) Subjects deemed unsuitable by the investigator.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Kazuhiko
Middle name
Last name Takano

Organization

Medical Corporation Hokubukai Utsukushigaoka hospital

Division name

Clinical Pharmacology Center

Zip code

004-0839

Address

61-1, Sinei, Kiyota-ku, Sapporo, Hokkaido, 004-0839, Japan

TEL

011-882-0111

Email

takano@ughp-cpc.jp


Public contact

Name of contact person

1st name Machiko
Middle name
Last name Nishioka

Organization

KOBELCO ECO-SOLUTIONS CO., LTD.

Division name

Technical Develop Center

Zip code

651-2241

Address

1-1-4, Murotani, Nishi-ku, Kobe 651-2241, JAPAN

TEL

078-992-6957

Homepage URL


Email

nishioka.machiko@kobelco.com


Sponsor or person

Institute

Medical Corporation Hokubukai Utsukushigaoka hospital

Institute

Department

Personal name



Funding Source

Organization

KOBELCO ECO-SOLUTIONS Co.,Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Medical Corporation Hokubukai Utsukushigaoka Hospital

Address

61-1, Shinei, Kiyota-ku, Sapporo, 004-0839, Japan

Tel

011-882-0111

Email

matsuda@ughp-cpc.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 01 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2021 Year 01 Month 21 Day

Date of IRB


Anticipated trial start date

2021 Year 01 Month 25 Day

Last follow-up date

2021 Year 05 Month 15 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 01 Month 24 Day

Last modified on

2021 Year 09 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049168


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name